Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05177510

Mifepristone Outpatient Labour Induction

The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID-19 pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine. Proving the efficacy and safety of Mifepristone would significantly reduce pre-labour admission rates and hospital length of stay for pregnant women, who are at particularly higher risk of COVID-19, and reduce delivery costs.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Chelsea and Westminster Hospital

London, United Kingdom

Location status: Recruiting

Location contact

Research Midwife

CONTACT

+442033152560

About this study

The study is a double blinded, two arms, multi-centre randomised controlled clinical trial to investigate the clinical effectiveness, safety and resource utilisation of intervention for the induction of labour in women admitted to the hospital. Subjects will be randomised 1:1 to one of the two arms to receive:

Arm 1: Mifepristone + standard of care Arm 2: Placebo + standard of care

The study treatment will commence from the administration of the Mifepristone or placebo. The participants will be assessed 2 days after treatment regimen will be completed as an in-patient.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women between 36+5 and 41+5 weeks of gestation
  • Singleton pregnancy
  • Aged 18 years or older
  • Unfavourable cervix (Bishop Score less than or equal to 6)
  • The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.

Exclusion criteria

  • Breech presentation
  • Early labour
  • Contraindication to vaginal birth (placenta praevia, transverse lie, known or suspected cephalo-pelvic disproportion or other factor contraindicated to vaginal birth in the opinion of the investigator)
  • Fetal growth restriction with oligohydramnios and/or abnormal Dopplers
  • Presence of reduced fetal movements requiring urgent delivery, abnormal CTG or recent antepartum haemorrhage requiring immediate delivery
  • Medical conditions:

i. sexually transmitted infections (active infections only) ii. bleeding disorders, on anticoagulants, steroid or aspirin therapy iii. prior uterine operations (Caesarean Section or myomectomy)

  • Contra-indications to mifepristone including chronic adrenal, hepatic, renal failure
  • Hypersensitivity to mifepristone or to any excipients, or malnutrition
  • Severe asthma uncontrolled by therapy and inherited porphyria
  • Any investigational drug with an expected interaction with mifepristone which has been administered within 30 days prior to the trial drug administration.

Treatment and study plan

Mifepristone

Drug

Progestin Antagonist

Placebo

Drug

Placebo

Primary outcomes

  1. Measure of women in labour or delivered within 2 days of intervention

    Time frame: up to 2 days after administration of intervention

    To determine proportion of women who do not require an induction of labour within 2 days of intervention with mifepristone (superiority).

Secondary outcomes

  1. Change in clinical outcomes

    Time frame: up to 6 weeks after delivery

    Occurrence of changes in clinical outcomes such as cervical ripening and interval to delivery.

  2. Determine whether intervention reduces resource utilisation and patient experience

    Time frame: after delivery and up to 6 weeks after delivery

    Patient reported outcomes will be collected following administration of questionnaires after delivery and up to 6 weeks after delivery

  3. To assess the efficacy and safety of Mifepristone for the outpatient induction of labour

    Time frame: up to 6 weeks after delivery

    Incidence and severity of adverse events in maternal and neonatal

Study contacts

Contact information is provided by the study sponsor or research team.

Arnold Xhikola

CONTACT

[email protected]

+442033156825

Tess Cheetham

CONTACT

[email protected]

+442033156825

Sponsors and collaborators

Lead sponsor

Chelsea and Westminster NHS Foundation Trust

Other

Registry information

Acronym: MOLI

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jan 4, 2022
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.